Back to search results

MIVetsCan: Cannabidiol (CBD) for Chronic Pain in Veterans

This study, called MIVetsCan: Cannabidiol (CBD)-Care Trial, is looking at how cannabidiol (CBD), a part of cannabis (also known as marijuana), affects chronic pain in Veterans. The goal is to see if CBD can help improve pain symptoms. You would be randomly assigned to receive either Epidiolex (CBD) or a placebo (an inactive substance) for 28 days. Researchers will then compare how much your pain has changed between the two groups. To join, you must be an Armed Services Veteran, at least 18 years old, able to read and speak English, and already enrolled in the MIVetsCan Pain Registry for at least four weeks.

Study design
This is an interventional study planning to enroll 468 participants. You would be randomly assigned to receive either Epidiolex (CBD) or a placebo.
What's involved
You would take either Epidiolex or a placebo for 28 days, with suggested dosing of 0.2 mL in the morning and 0.2 mL in the evening (up to 1.2 mL per day).
Compensation
Not stated in the trial record.
Follow-up
Your global impression of change will be measured at the end of treatment on Day 28.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06213233

MIVetsCan: Cannabidiol (CBD)-Care Trial

Recruiting
PHASE2Ages 18+InterventionalTreatment
Kevin Boehnke
~468 participants
Updated 2026-06-01 on ClinicalTrials.gov
What's tested:PlaceboCannabidiol

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Global impression of change (PGIC) between groups at end of treatment (Day 28)
Measured over Day 28

Conditions

Pain, Chronic

Explore related trials

Chronic Pain

Where it's being run

1 sites across 1 states
Michigan1

Study leadership

  • Kevin Boehnke, PhD · PRINCIPAL_INVESTIGATOR · University of Michigan

Who to contact

Catherine Klida
[email protected]
734-998-8010
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Ability to read and speak English sufficiently to allow for written informed consent and patient-reported outcomes measures
Armed Services Veteran
All participants must have been enrolled in the MIVetsCan Pain Registry (HUM00223894) for at least 4 weeks and agree to continue participation in that study.
Reports moderate to severe chronic pain defined by protocol
Currently using or interested in using cannabis for pain management
Self-reported willingness to refrain from or not increase current Tetrahydrocannabinol (THC) or other cannabis product use (including CBD) during the study intervention or other cannabinoid use during the study intervention
Individuals of reproductive potential must agree to use acceptable birth control per protocol
Participants must also agree not to donate sperm or eggs during study drug administration
Willingness to attend all study visits (may be done virtually)
Ability to take and to swallow the study medication and be willing to adhere to the treatment regimen
Willingness to wear Fitbit or other similar sensor for passive-data collection
Willingness to fill out daily diary via smartphone to assess symptom status, study drug use, and other cannabis use

Exclusion

Not an Armed Services Veteran
Inability to provide informed consent (e.g., cognitive impairment, unable to sufficiently communicate in English)
Participant reports pregnancy or are nursing
Planning to move out of a state with legal recreational marijuana use during course of study
Risk for imminent harm - Suicidal ideation or wish to die as assessed per protocol
Any impairment, activity, behavior, or situation that in the judgment of the study team would prevent satisfactory completion of the study protocol
Participation in any other clinical trials over the course of this study
Medical or psychiatric conditions that in the judgment of study personnel would preclude participation in this study (e.g., psychosis, suicidal ideation; note that stable anxiety and depression are not exclusions)
Having a serious or unstable hepatic disease (e.g., non-alcoholic fatty liver disease or liver cirrhosis)
Individuals with major neurological disorders, such as dementia, Parkinson's disease, cognitive impairment, epilepsy, and seizures
Recent/new diagnosis of cancer within the past 3 years (other than localized melanoma, localized basal cell carcinoma, localized squamous cell carcinoma treated or untreated)
Current valproate and clobazam use per self-report or medical records
Self-reported allergies to sesame oil or cannabis/cannabinoids

What this trial measures

  • Global impression of change (PGIC) between groups at end of treatment (Day 28)Day 28

    This is a 1-item survey that measures patient perceptions of intervention success. This survey is scored from 1 to 7, where lower scores indicate a better outcome.